Pepscan Therapeutics Achieves Milestones in Research Collaboration With Janssen R&D Ireland
LELYSTAD, The Netherlands, February 8, 2012 /PRNewswire/ –
Pepscan Therapeutics B.V., the Netherlands based biotechnology firm focusing on
protein mimicry technology for the generation of novel therapeutics, today announced that
it has achieved two milestones in the Research Collaboration with Janssen R&D Ireland,
formerly Tibotec Pharmaceuticals, and received undisclosed payments.
In the collaboration, Pepscan has discovered novel peptides with potential therapeutic
utility using its proprietary peptide array platform for high throughput synthesis and
screening of conformationally stabilized CLIPS peptides.
“The achievement of these milestones demonstrates the effectiveness of our high
throughput peptide array technology for the discovery of novel peptides with excellent
activity and proteolytic stability,” said Wim Mol, CEO of Pepscan. “We consider this
achievement a further expression of our expertise in the field of peptide lead discovery
Pepscan Therapeutics B.V. is a privately held company based in Lelystad, The
Netherlands. Pepscan is using its proprietary high throughput CLIPS protein mimicking
technology for the development of novel constrained therapeutic peptides and immunogens.
Besides its pipeline of proprietary anti-GPCR monoclonal antibody products, Pepscan has
various ongoing collaborations with leading pharmaceutical and biotech companies to
develop novel therapeutics based on the proprietary CLIPS technology.
CLIPS (Chemical LInkage of Peptides onto Scaffolds) is a technology to present one or
more peptides in a structurally constrained configuration. These molecules behave as
functional mimics of structurally complex protein domains. CLIPS therapeutic peptides have
been shown to exert excellent activity and stability. CLIPS peptides are also used as
superior immunogens for antibody generation against disease relevant protein targets. This
is especially valuable in the case of proteins that are inaccessible as recombinant
proteins, such as GPCRs.
SOURCE Pepscan Therapeutics B.V.